Freespira is an FDA-approved digital therapeutic solution to treat panic attacks, panic disorders, and PTSD symptoms over 28 days by training users to normalize respiratory irregularities.
The Freespira platform combines a proprietary sensor, a nasal cannula, connected tablet, patented software, and telehealth services to provide real-time breathing regulation exercises with a coach. The sessions are 17 minutes long and are conducted twice a day for 4 weeks. Patients can seek treatment through their health plans, insurers, or healthcare providers.
Founded in 2013, the Washington-based company (previously known as Palo Alto Health Sciences) raised USD 10 million in a Series D funding round that brought its total funding to USD 20.2 million.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.